Skip to main content

Advertisement

Table 2 Bivariate and multivariable analysis for overall survival

From: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer

Characteristic Crude HR (95% CI) P-value* (bivariatea) Adjusted HR (95% CI) P-value* (multivariablea)
Primary tumor location
 Right vs. Left 2.29 (1.46–3.62) <0.001 1.84 (1.10–3.09) 0.021
Age
 >60 years vs. ≤ 60 1.06 (0.76–1.47) 0.750 1.07 (0.75–1.51) 0.720
Gender
 Female vs. Male 0.92(0.65–1.30) 0.623 0.97 (0.66–1.40) 0.852
Stage at presentation
 Stage IV vs. Stage I-III 1.12 (0.77–1.63) 0.554   
Histologic grade
 P/D or SRC vs. W/D or M/D 4.35 (2.21–8.57) <0.001 3.08 (1.49–6.34) 0.002
Presence of liver metastasis
 Yes vs. No 1.29 (0.91–1.82) 0.156   
Presence of lung metastasis
 Yes vs. No 0.84 (0.61–1.15) 0.279   
Presence of peritoneal metastasis
 Yes vs. No 2.91 (1.79–4.75) <0.001 2.05 (1.17–3.60) 0.013
Number of metastasized organs
 ≥ 2 vs. 1 1.10 (0.80–1.52) 0.540   
BRAF
 Mutant vs. Wild-type 3.24 (1.94–5.43) <0.001 2.84 (1.60–5.03) <0.001
PIK3CA
 Mutant vs. Wild-type 1.97 (0.80–4.84) 0.138   
  1. Abbreviations: HR hazard ratio, CI confidence interval, P/D poorly differentiated, SRCC signet ring cell carcinoma, W/D well-differentiated, M/D moderately differentiated
  2. * P-value by Cox’s proportional hazards regression
  3. aClinically meaningful variables and those with p < 0.05 by bivariate analysis were entered into the multivariable analysis model